丹红注射液对合并代谢综合征的非ST段抬高型急性心肌梗死患者血清CD137、高敏C反应蛋白和高半胱氨酸水平的影响  

Effects of Danhong on the serum levels of CD137, high-sensitivity C-reactive protein （hs-CRP） and homocysteine in patients with non-ST elevation acute myocardial infarction complicating metabolic syndrome

作　　者：颜永进[1] 邓海鹏[2] 郭宗峰[3] 刘玲玲[1] 陆洋[1] 王世亚[1] 顾顺忠[1] 丁宏胜[1] 张跃明[1] 潘闽[4] 朱健华[4] 吉华亮[2] 

机构地区：[1]南通大学附属海安医院心血管内科,226600 [2]南通大学附属海安医院医务科,226600 [3]南通大学附属海安医院麻醉科,226600 [4]南通大学附属医院心血管内科,226001

出　　处：《国际中医中药杂志》2014年第12期1092-1095,共4页International Journal of Traditional Chinese Medicine

摘　　要：目的：探讨丹红注射液对合并代谢综合征的非ST段抬高型急性心肌梗死患者血清CD137、高敏C反应蛋白（hs-CRP）和高半胱氨酸水平（Hcy）的影响。方法纳入合并代谢综合征的非ST抬高型心肌梗死患者126例，按随机数字表法随机分为常规治疗组和丹红治疗组，每组63例。常规治疗组患者给予常规治疗，丹红治疗组在常规治疗组基础上给予丹红注射液静脉滴注，20 ml/次。检测患者入院时和治疗后10 d时血清CD137、hs-CRP和Hcy水平。采用Gensini评分法评价冠状动脉疾病严重程度。结果两组治疗后，血清CD137、hs-CRP、Hcy均较同组治疗前明显降低（常规治疗组t值分别为12.393、17.408、9.458，丹红治疗组t值分别为16.110、17.573和13.481，P均＜0.01），丹红治疗组较常规治疗组下降更显著（t值分别为2.815、3.224和3.157，P均＜0.01）。126例患者术前CD137、hs-CRP与冠状动脉狭窄程度积分（Gensini积分）呈显著正相关（r分别为0.720和0.562，P均＜0.01）。结论合并代谢综合征的非ST段抬高型急性心肌梗死患者血清CD137、hs-CRP水平与冠状动脉疾病程度相关，静脉滴注丹红可能通过降低CD137、hs-CRP对冠状动脉疾病有一定的保护作用。Objective To investigate effects of Danhong on the serum levels of CD137, high-sensitivity C-reactive protein （hs-CRP） and homocysteine （Hcy） in patients with non-ST elevation acute myocardial infarction complicating metabolic syndrome. Methods A total of 126 patients with non-ST elevation acute myocardial infarction complicating metabolic syndrome were enrolled and randomly divided into a conventional treatment group and a Danhong treatment group using a random-digit table, with 63 patients in each group. All patients underwent angiography or percutaneous coronary intervention. The patients in the Danhong treatment group treated with intravenous Danhong 20 ml on the basis of conventional treatment for 1 week. The serum levels of CD137, hs-CRP and Hcy were measured at hospital admission and 10 days after treatment. The severity of coronary artery disease was assessed by the Gensini-score. Results The levels of CD137, hs-CRP and Hcy in both groups after treatment were significantly lower than before treatment （conventional treatment group： t 12.393, 17.408 and 9.458; Danhong treatment group： t 16.110, 17.573 and 13.481; all P〈0.01）, and the Danhong treatment group were significantly decreased than the conventional treatment group （t 2.815, 3.224 and 3.157, all P〈0.01）. The serum levels of CD137 and hs-CRP before treatment were significantly correlated with Gensini scores in 126 patients （r 0.720 and 0.562,all P〈0.01）. Conclusions The serum levels of CD137 and hs-CRP are significantly correlated with the severity of coronary artery disease, intravenous Danhong may has protective effect for coronary artery disease via decreasing CD137 and hs-CRP.

关 键 词：心肌梗死 代谢综合征X 抗原 CD137 C-反应蛋白 高半胱氨酸 丹红注射液 

分 类 号：R542.22[医药卫生—心血管疾病]